Enumeration and Functional Evaluation of Regulatory T-cells in Psoriasis Patients Before and After Treatment with: Calcipotriol/Betamethasone, Acitretin, Narrow-Band UVB and Anti-TNF a Therapy (Etanercept, Adalimumab and Infliximab) - Regulatory T-cells in Psoriasis Patients as Targets for Therapy

niversity of Aberdeen0 个研究点目标入组 40 人开始时间: 2010年3月18日最近更新: 2014年4月7日

适应症

试验速览

暂无简介。

•Male and female patients in the age range from 18 to 70 who are diagnosed with moderate to severe psoriasis.
•Patients must be treatment free for at least 2 weeks for topical application and 4 weeks for systemic treatment of psoriasis.
•Women of child bearing potential must be on reliable contraception.
•Patients in whom a decision to treat with one of the following therapies has already been made based on normal clinical care:
•oNeotigason
•oNarrow-band UVB
•oEtanercept
•oAdalimumab
•oInfliximab
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Children below 18 years and patients over 70 years.
•Pregnant and lactating patients.
•Patients who are known to have immunosuppressive disease (e.g. HIV) or on any immunosuppressive therapy.

发起方

niversity of Aberdeen